Multiplexed cancer cell line screening

PRISM rapidly screens a wide range of drugs across more than 900 human cancer cell line models using a high-throughput, multiplexed approach.

Sensitive viability screening across an extensive, diverse cell line collection

Large-scale cancer cell line screening is critical to oncology drug discovery and development to better understand how drugs work. Traditional phenotypic screening tests only one cell line at a time using a lot of resources and taking a lot of time. Generating data for a small subset of cell lines results in an incomplete understanding of your drug.

Using PRISM, we accelerate the screening process by employing a novel DNA barcode-based approach that enables simultaneous high-throughput viability analysis of over 900 cell lines from over 45 cancer subtypes. Our extensive cell line collection captures the diversity of human cancers to provide a comprehensive evaluation of oncology drug candidates.